ClinicalTrials.gov
public full text
Public Domain
Tauropace to Prevent Cardiac Implantable Device Infections in Heart Failure Patients
The main purpose of the study is to evaluate the ability of the Tauropace to reduce major cardiac implantable electronic device (CIED) infections through 12-months post-procedure following CIED in heart failure participants. The secondary endpoint is to prospectively characterize the performance of Tauropace in participants whose CIED system includes a transvenous RV defibrillation lead.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- DYNAMX Bioadaptor ImplanTation for the trEatment of Complex Coronary Lesions#878697
- Assessment of Validity and Reliability of the Turkish Version of the Quality of Life and Related Events Assessment Scale for Pacemaker Patients#1048079
- Safety of Smartphones Among Patients With Cardiac Implantable Electronic Devices#845716
- Characterization of the Quality of Electroconvulsive Therapy Among Older Medicare Beneficiaries.#275607
- Diagnostic Study of Structural Heart Disease Based on Cardiac Electromechanical Signals#1008085
Record · ID 1150964
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive